SideROS is a preclinical-stage biotech company focused on accelerated development of innovative small molecules targeting tumor cells metabolism in high-risk cancers with poor prognosis. The company bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to metastasis and relapse.
Year of creation: 2019
Line of business: Biopharma
Institut Curie: Behind the technology and institutional co-founder
The company's first lead product, the ironomycin, is a chemical molecule, highly active in vitro and in vivo. This molecule quantitatively accumulates in lysosomes of persistent cancer cells. There, ironomycin sequesters iron, involved in the maintenance of persistent cancer cell and provokes cell death. The process of ironomycin manufacturing consists of two steps of chemical modifications and is a huge competitive advantage regardless the immunotherapy strategies (i.e. CAR-T).
SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.
More about SideROS: